Analyzing SpectraScience (SCIE) and Vision Sciences (CGNT)

SpectraScience (OTCMKTS:SCIE) and Vision Sciences (NASDAQ:CGNT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for SpectraScience and Vision Sciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SpectraScience 0 0 0 0 N/A
Vision Sciences 0 2 0 0 2.00

Vision Sciences has a consensus target price of $4.38, suggesting a potential upside of 13.64%. Given Vision Sciences’ higher probable upside, analysts clearly believe Vision Sciences is more favorable than SpectraScience.

Volatility and Risk

SpectraScience has a beta of 3.14, suggesting that its share price is 214% more volatile than the S&P 500. Comparatively, Vision Sciences has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.


This table compares SpectraScience and Vision Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SpectraScience N/A N/A N/A
Vision Sciences -1.57% -1.39% -1.21%

Insider and Institutional Ownership

0.0% of SpectraScience shares are owned by institutional investors. Comparatively, 14.5% of Vision Sciences shares are owned by institutional investors. 0.5% of SpectraScience shares are owned by insiders. Comparatively, 62.7% of Vision Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SpectraScience and Vision Sciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SpectraScience N/A N/A -$4.46 million N/A N/A
Vision Sciences $56.32 million 4.16 -$880,000.00 ($0.01) -385.00

Vision Sciences has higher revenue and earnings than SpectraScience.


Vision Sciences beats SpectraScience on 5 of the 9 factors compared between the two stocks.

SpectraScience Company Profile

SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps. In addition, it engages in developing an esophageal diagnosis application for the detection of pre-cancerous and cancerous tissues in various tissues of the body. The company was formerly known as GV Medical, Inc. and changed its name to SpectraScience, Inc. in October 1992. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California.

Vision Sciences Company Profile

Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.

Receive News & Ratings for SpectraScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpectraScience and related companies with's FREE daily email newsletter.

Leave a Reply